Grifols (GRFS) Net Cash Flow Growth (1y) (2011 - 2020)
Grifols (GRFS) Net Cash Flow Growth (1y) (2011 - 2020) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
-83.55% |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
-568.73% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-85.99% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
1,265.92% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-95.55% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
191.97% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
103.60% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
42.41% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
-227.06% |
| 10 |
Grifols |
6.05 Bn |
5.09 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2020 |
75.96% |
| Dec 31, 2019 |
-124.72% |
| Mar 31, 2019 |
-317.42% |
| Dec 31, 2018 |
-72.95% |
| Jun 30, 2018 |
-314.28% |
| Mar 31, 2018 |
-93.45% |
| Dec 31, 2017 |
6,845.21% |
| Dec 31, 2016 |
94.44% |
| Sep 30, 2016 |
-322.73% |
| Mar 31, 2013 |
11,593.55% |
| Dec 31, 2012 |
-638.75% |
| Sep 30, 2012 |
-94.60% |
| Jun 30, 2012 |
0.95% |
| Mar 31, 2012 |
100.68% |
| Dec 31, 2011 |
532.57% |
| Sep 30, 2011 |
4,801.27% |
